Get the Stockscreener App
10.99
2.83%
-0.32
After Hours:
10.30
-0.69
-6.28%
Wave Life Sciences Ltd stock is traded at $10.99, with a volume of 866.64K.
It is down -2.83% in the last 24 hours and down -23.94% over the past month.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$11.31
Open:
$11.39
24h Volume:
866.64K
Relative Volume:
0.61
Market Cap:
$1.68B
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-19.98
EPS:
-0.55
Net Cash Flow:
$-20.55M
1W Performance:
-4.77%
1M Performance:
-23.94%
6M Performance:
+85.96%
1Y Performance:
+133.33%
1-Day Range:
$10.96
$11.46
1-Week Range:
$10.57
$12.03
52-Week Range:
$3.50
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
10.99 | 1.68B | 113.31M | -57.51M | -20.55M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
(WVE) Trading Advice - Stock Traders Daily
Wave Wants To Put The Joy Back Into Weight-Loss Drugs - News & Insights
Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential? - Yahoo Finance
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation - GlobeNewswire
Wave Life Sciences Advances Obesity Drug WVE-007, Reports Strong DMD Treatment Results - StockTitan
Barclays PLC Has $1.31 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
WAVE Life Sciences (FRA:1U5) Cash From Discontinued Investi - GuruFocus.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.22 Average Target Price from Brokerages - MarketBeat
12 Best Growth Stocks Under $25 to Buy Now - Insider Monkey
Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25? - Yahoo Finance
How to Take Advantage of moves in (WVE) - Stock Traders Daily
Wave Life Sciences Is A Buy On Pipeline Prospects (WVE) - Seeking Alpha
Wave Life Sciences (NASDAQ:WVE) Trading Down 4%Here's What Happened - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Stock Price Up 7.7%What's Next? - MarketBeat
Learn to Evaluate (WVE) using the Charts - Stock Traders Daily
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Barclays PLC - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Stock Price Down 2.6%Here's Why - MarketBeat
Wave files clinical trial application for WVE-007 - BioWorld Online
State Street Corp Has $19.03 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity - The Manila Times
Wave Life Sciences Announces Submission of First Clinical - GlobeNewswire
Wave Life Sciences Advances Novel Obesity Drug WVE-007 Targeting INHBE Gene; Clinical Trials Set for 2025 - StockTitan
WAVE Life Sciences (FRA:1U5) Other Long-Term Liabilities : €7.09 Mil (As of Sep. 2024) - GuruFocus.com
WAVE Life Sciences (FRA:1U5) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
(WVE) Investment Analysis - Stock Traders Daily
Y Intercept Hong Kong Ltd Has $242,000 Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wellington Management Group LLP Reduces Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
WaVe Life Sciences' SWOT analysis: RNA editing pioneer's stock faces pivotal year - Investing.com Australia
Point72 Asset Management L.P. Has $230,000 Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Fmr LLC Raises Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Can Sai Life Sciences ride the global CRDMO wave? A detailed IPO analysis - Dalal Street Investment Journal
Jacobs Levy Equity Management Inc. Sells 262,075 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Duchenne Muscular Dystrophy Pipeline Insights 2024: - openPR
RTW Investments LP Makes New Investment in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
486,023 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Acquired by Polar Asset Management Partners Inc. - MarketBeat
Maven Securities LTD Purchases Shares of 850,000 Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Cinctive Capital Management LP Has $2.92 Million Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Baker BROS. Advisors LP Invests $2.82 Million in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Walleye Capital LLC Invests $4.94 Million in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
WAVE Life Sciences (STU:1U5) Pre-Tax Income : €-130.19 Mil (TTM As of Sep. 2024) - GuruFocus.com
WAVE Life Sciences (FRA:1U5) Financial Strength : 6 (As of Sep. 2024) - GuruFocus.com
Wave Life Sciences CEO Paul Bolno sells $750,000 in shares - Investing.com India
Wave Life Sciences CEO Paul Bolno sells $750,000 in shares By Investing.com - Investing.com Canada
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):